TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed unifocal or multifocal transitional cell carcinoma of the bladder no greater than 5 cm, with evidence of muscle invasion documented by transurethral resection of the bladder (TURB), with no residual visible or palpable tumor mass at the end of TURB Stage II or III (T2-T3, N0, M0) No squamous cell or adenocarcinoma No evidence of pelvic lymph node involvement by CT scan or MRI No evidence of hydronephrosis No evidence of distant metastases No disease in the prostatic urethra~PATIENT CHARACTERISTICS: Age: Under 76 Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 11 g/dL Hepatic: Not specified Renal: See Disease Characteristics Creatinine clearance greater than 50 mL/min Cardiovascular: No progressive ischemic cardiopathy Other: No reduced bladder capacity No prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix treated by hysterectomy~PRIOR CONCURRENT THERAPY: Biologic therapy: Prior immunotherapy for superficial disease allowed No concurrent growth factors Chemotherapy: No prior systemic chemotherapy Prior intravesical chemotherapy or intravesical BCG allowed Endocrine therapy: Not specified Radiotherapy: No prior pelvic radiotherapy Surgery: No prior surgery for bladder cancer except transurethral resection of the bladder

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Scale of Well-Being Assessment (SIWA) in Patients With Alzheimer's Disease or a Related Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled patients must have given themselves, or through a trusted person referred to the Article L. 1111-6 of the Code of Public Health, failing thereof, by the family, or, a person maintaining close and stable ties. For adults under guardianship, permission must be given by the legal representative of the person. The research will benefit from the backing of persons Protection Committee (PPC) prior to its implementation.~* Patient living in one of the nursing home or hospital services in the project;~* Patient with Alzheimer's or a related disease~Exclusion Criteria:~* severe, progressive or unstable pathology, which may interfere with the evaluation variables;~* deafness or blindness may compromise patient assessment

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient living in nursing home (Type: None): Patient with an Alzheimer Disease or related disorder living in nursing home.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for Bone Marrow Biopsy:~1. Patients with Genitourinary (GU) Cancers and presence of existing patient derived xenograft or planned collection of tumor for PDX generation~2. Age ≥ 18 years.~3. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.~4. Ability to undergo bone marrow biopsy~5. Laboratory requirements (Hematocrit 30%, Platelets 75,000 + 10\^6/l and WBC 4000 X 10\^6/l)~6. Karnofsky performance status \>70%~Exclusion Criteria for Bone Marrow Biopsy:~1. Participants with serious concurrent chronic or acute illness that would affect the safety of a bone marrow biopsy.~Inclusion Criteria for Tumor Biopsy~1. Patients with prostate cancer~   a. Biopsies in this study for diseases other than prostate cancer are not permitted.~2. Age ≥ 18 years.~3. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.~4. Planned or willing to undergo a tumor biopsy. Biopsies may be for research or clinical purposes depending on the treating provider for men with prostate cancer. Biopsies in this study for diseases other than prostate cancer are not permitted~   1. For research only biopsies: At least one lymph node or bone metastatic amenable to a minimum risk biopsy in the opinion of the treating physician.~  2. For clinical purpose biopsies: There are no location or risk requirements.~5. Laboratory requirements (Hematocrit 30%, Platelets 75,000 X 10\^6/l and WBC 4000 X 10\^6/l)~6. Karnofsky performance status \>70%~Exclusion Criteria for Tumor Biopsy:~1. Participants with serious concurrent chronic or acute illness that would affect the safety of a tumor biopsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects from which PDXs have been generated. (Type: None): Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
- Subjects without an existing PDX (Type: None): Subjects with prostate cancer amenable to a tumor biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed large cell, undifferentiated, or poorly differentiated stage IV lung cancer unlikely to have a curative response to existing standard regimens~* Measurable disease by MRI or CT scan~  * At least 2 cm in diameter~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections~* No other concurrent serious disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agent~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agent~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agent allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolomic Profiling of Novel Mediators of Vascular Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 or older~* Type 2 diabetes mellitus~Exclusion Criteria:~* Type 1 diabetes mellitus~* Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone), an amylin analog (Symlin \[pramlintide\]), or incretin mimetics (Byetta \[exenatide\])~* Pregnancy~* Uncontrolled hypertension, \> 180/100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Blood sampling and brachial artery ultrasound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical indication for left and right heart catheterization~* Willing and able to provide informed consent~* Male or female 18 years of age or greater~* Symptomatic heart failure (≥ NYHA Class II)~* Ejection fraction ≤ 35%~* Patient is in sinus rhythm~* Patient is considered to be in suitable health in the opinion of the investigator, as determined by:~  o A pre-study physical examination with no clinical abnormalities which in the opinion of the investigator would preclude participation in the study other than physical symptoms or signs consistent with stable heart failure~* For female patients only: Post-menopausal or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant for up to 90 days following the study, and she is using contraceptive drugs or devices~Exclusion Criteria:~* Acute myocarditis~* Hypertrophic, restrictive, or constrictive cardiomyopathy~* Congenital heart disease~* Known left ventricular thrombus~* Significant stenotic valvular disease (severe aortic stenosis, mitral stenosis)~* Poorly controlled hypertension (SBP \> 180 mmHg)~* Pacemaker dependent ventricular rhythm~* Detectable troponin or CK-MB \> ULN at any timepoint within 14 days of enrollment~* Acute coronary syndrome or revascularization procedure within 30 days of enrollment~* ≥ 50% stenosis of the left main coronary artery~* Plan for immediate revascularization procedure (PCI or CABG)~* GFR ≤ 35 ml/min/1.73 m2 by Modification of Diet in Renal Disease (MDRD) Equation or need for renal replacement therapy~* Known hepatic impairment (total bilirubin \> 3 mg/dL, or ALT and AST \> 2 times the upper limit of normal)~* Has received an investigational drug or device within 30 days before enrollment~* Has had any prior treatment with CK-1827452

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
- Cohort 2 (Type: EXPERIMENTAL): ≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic adenocarcinoma of the pancreas.~2. Adequate hematological parameters:~   Hemoglobin \>/= 9.5 g/dL \[SI units, 5.9 mmol/L\] WBC \>/= 3000/mm3 \[SI units, \>/= 3 x 109/L\] Platelets \>/= 100,000/mm3 \[SI units, \>/= 100 x 109/L\]~3. Adequate baseline liver function:~   Total Bilirubin \< 3x ULN and~   Without liver metastases:~   AST (SGOT) \</= 2.5 x ULN ALT (SGPT) \</= 2.5 x ULN~   With liver metastases:~   AST (SGOT) \</= 5 x ULN ALT (SGPT) \</= 5 x ULN~4. Serum creatinine \</= 1.5 mg/dL \[SI units, 132 µmol/L\].~5. Performance status ECOG 0-1.~6. Male or female 18 - 75 years inclusive.~7. Minimum life expectancy of 3 months.~8. Written informed consent.~Exclusion Criteria:~1. Treatment with chemotherapy for pancreatic cancer.~2. Treatment with other investigational drugs within the last 4 weeks prior to inclusion~3. Immune-suppressive therapy \<4 weeks prior to inclusion~4. Chronic corticosteroid use except for asthma inhalers / topical use~5. Radiotherapy within 8 weeks of randomisation.~6. Other prior malignancies except for adequately treated non-melanoma skin cancers (BCC, SCC) and carcinoma in situ of the cervix.~7. Known diagnosis of HIV (AIDS), Hepatitis B, C.~8. Known history of or co-existing autoimmune disease.~9. Known CNS metastases.~10. Clinically significant serious disease or organ system disease not currently controlled on present therapy.~11. Pregnancy or lactation.~12. Women of childbearing potential not using reliable and adequate contraceptive methods\*~13. Known sensitivity to any components of vaccine, gemcitabine or GM-CSF.~14. Unable for any other reason to comply with the protocol (treatment or assessments).~    * Adequate contraceptive methods are defined as the use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; or women who are practising abstinence; or where the partner is sterile, for example a vasectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine (Type: ACTIVE_COMPARATOR): Gemcitabine alone treatment.
- GV1001 (Type: EXPERIMENTAL): GV1001 in sequential combination with Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All individuals with NF1 (neurofibromatosis type 1), based on NIH diagnostic criteria, who are between the ages of 25 and 40 years, may participate in this study. All participants will be enrolled in the study and then screened for serum 25(OH)D levels, and all individuals with levels between 9 and 29ng/ml (inclusive) are eligible for vitamin D supplementation -~Exclusion Criteria:~1. diagnosis of Paget's disease, hyperthyroidism, hyperparathyroidism, or other medical condition that affects bone health~2. they foresee that they will be unable to comply with the two-year study protocol~3. Pregnant, planning to conceive within the next two years, or is less than 6 months post-delivery or lactation.~4. vitamin D supplementation in the last 3 months equal to or greater than 600IU per day~5. oral or IV glucocorticoid use for over 3 months~6. bisphosphonate therapy for more than 3 months~7. calcitonin therapy for more than 3 months~8. calcium supplementation in last 3 months equal to or greater than 1000mg per day~9. malignant peripheral nerve sheath tumor (MPNST)~10. history of kidney stones in last 5 years~11. individuals with metal instrumentation in spine or hip that preclude accurate DXA interpretation.~12. inability to obtain blood samples on routine venipuncture~13. anti-epileptic medical therapy~14. anticoagulant medical therapy

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- cholecalciferol 600 IU (Type: ACTIVE_COMPARATOR): cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
- cholecalciferol 4,000 IU (Type: ACTIVE_COMPARATOR): Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Restoring Masticatory Function to Treat Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completely dentate (except for the third molars; including if they were treated before enrollment by conventional or implant-supported fixed prosthesis allowing similar potential comfortable chewing on both sides)~* Normal Angle Class I occlusion~* Self-reported pain-intensity scores from 4 to 9 in a 0-10 visual analogue scale (VAS) or numerical pain rating scale (NRS).~* Chronic (over 6 months) joint and/or muscle pain, according to diagnostic criteria for temporomandibular disorders (DC/TMD), for which they had requested therapy~Exclusion Criteria:~* Psychosis~* Major depression~* Substance abuse~* Cognitive impairment~* Addiction to morphine or derivates~* Litigation or asking for disability/retirement compensation for chronic pain~* Dental care professionals~* Orthodontic therapy during the last 2 years~* Patients with any pain that is more severe, in the same location as, or cannot be clearly distinguished from TMD pain~* Individuals for whom minimally invasive occlusal adjustment could not achieve occlusal equilibration, including: Over 2 mm of difference between the maximal intercuspal position and the centric occlusion or over 4 mm of difference between upper and lower archs (or over 2mm on at less one side) measured: between the mesial fosses of first upper premolars with respect the buccal cusps of the first lower premolars; and/or between the mesiopalatal cusp of the first upper molars respect to the central (mesial) fossae of the first lower molar.~* Severe periodontal disease with grade 3 mobility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Occlusal adjustment therapy (Type: EXPERIMENTAL): Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
- Placebo occlusal adjustment therapy (Type: PLACEBO_COMPARATOR): Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thoracoscopic Vascular Rings Chart Review

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing vascular ring division at Children's Healthcare of Atlanta at Egleston Hospital between 2001 and 2004

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Pneumothorax Following Endoscopic Valve Therapy in Patients With Severe Emphysema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FEV1 \< 50%, RV\>150%, TLC\>100%~* emphysema confirmed by computed tomography~* pO2 \>60 mmHg (with supplemental oxygen), pCO2 \< 55 mmHg (room condition)~* no significant collateral ventilation (assessed by fissure analysis and/or catheter-based measurement)~* no COPD exacerbation within the past 8 weeks~* daily use of \< 20 mg Prednisolon~* non-smoking for a minimum of 4 months prior to consent~* Patient has provided written informed consent~Exclusion Criteria:~* BMI \< 18 kg/m²~* clinically relevant bronchiectasis~* failed cardiac clearance: defined as myocardial infarction within last 6 weeks, decompensation of heart failure~* Prior lung resection (e.g. lobectomy)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modified medical care (Type: ACTIVE_COMPARATOR): Patients will undergo 48-hours bed rest after endoscopic valve implantation.
- Standard medical care (Type: NO_INTERVENTION): Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues